I like the fact they are obviously mining the gold instead of leaving it in the ground. Using the staff to investigate other usages of the platform during periods of waiting on other things appears to be a good idea.
It's actually quite amazing how quickly they've dealt with the Polymedix assets since picking them up out of bankruptcy. They've already had a Brilacidin phase 2b dose optimization trial for ABSSSI. Most playing biotech realize how quickly this trial was done.
It will be interesting to see the data coming out after the EU conference. Nothing will be held back after that.
The FDA decision on how to proceed next is the big mystery.
The data from the grant funded studies on gm- are also of major interest. I fully agree with your thinking there.
In Reply to 'To infinity and beyond!' I get what you mean and the prress release means- it is a surprise. Look forward to hearing more
Much more interested in hearing about gm - news/developments, as we all are
News 
Market Data 
Discover 
AI
